GF Fund Management CO. LTD. Buys Shares of 5,996 Exelixis, Inc. (NASDAQ:EXEL)

GF Fund Management CO. LTD. purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,996 shares of the biotechnology company's stock, valued at approximately $200,000.

A number of other large investors have also made changes to their positions in EXEL. Coppell Advisory Solutions LLC acquired a new position in Exelixis in the fourth quarter valued at about $25,000. Colonial Trust Co SC grew its position in shares of Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 765 shares during the period. Principal Securities Inc. increased its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 373 shares in the last quarter. Kestra Investment Management LLC bought a new stake in Exelixis during the 4th quarter worth approximately $39,000. Finally, UMB Bank n.a. raised its holdings in Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after buying an additional 553 shares during the period. Institutional investors own 85.27% of the company's stock.

Insider Buying and Selling

In related news, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $45.47, for a total value of $3,309,124.72. Following the transaction, the chief marketing officer now directly owns 465,393 shares of the company's stock, valued at $21,161,419.71. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Tomas J. Heyman sold 4,544 shares of Exelixis stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total value of $201,253.76. Following the completion of the transaction, the director now owns 32,470 shares in the company, valued at approximately $1,438,096.30. The trade was a 12.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 441,740 shares of company stock valued at $20,282,998 over the last 90 days. 2.82% of the stock is owned by corporate insiders.

Exelixis Trading Down 0.7%

Shares of NASDAQ:EXEL traded down $0.31 during trading on Friday, reaching $42.29. 710,442 shares of the stock were exchanged, compared to its average volume of 2,306,937. Exelixis, Inc. has a 12 month low of $20.40 and a 12 month high of $48.85. The stock has a 50-day moving average price of $38.35 and a 200-day moving average price of $36.32. The firm has a market cap of $11.53 billion, a PE ratio of 23.93, a PEG ratio of 1.13 and a beta of 0.25.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Piper Sandler lifted their target price on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Wall Street Zen downgraded Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Finally, Stifel Nicolaus lifted their price objective on shares of Exelixis from $36.00 to $38.00 and gave the company a "hold" rating in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $38.94.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.